drugset / Trial / NCT07118670
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
Timeline
- Start
- 2025-12-08
- Primary completion
- 2028-02
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aflibercept | Protein / enzyme biologic | 8 mg | Intravitreal |